Noramco™
Michael Schultz is a seasoned finance professional with extensive experience across various industries. Currently serving as Controller at Noramco™ since January 2021, Michael previously held key positions at The Chemours Company, including Supply Chain and Operations Finance Manager and Management Reporting Workstream Leader, contributing to finance transformation initiatives. Prior roles at DuPont spanned multiple senior finance analyst and managerial positions focused on cost analysis and strategic planning. Michael's career began at KPMG, where significant audit experience was gained, leading to the mentoring of junior associates and teamwork in international audit projects. Michael holds an MBA in Strategy and Finance from Yale School of Management and a BS in Accounting from Saint Joseph's University.
Noramco™
Noramco, headquartered in Wilmington, Delaware, is a global leader in the production of controlled substances for the pharmaceutical industry, for medicines used to treat attention deficit hyperactivity disorder, pain, addiction, and for abuse-deterrent formulations. We realize our success through a keen focus on commercial and operational excellence as well as continuing strategic growth. Our global footprint includes Athens, GA, Wilmington, DE and Neuhausen, Switzerland. Specialists in controlled substance development and manufacturing, Noramco is a partner to the pharmaceutical industry: – Focusing on high-purity controlled substances – Leveraging intellectual property to devise the most efficient routes to APIs – Providing analytical data, chemical and physical properties, stability studies and regulatory assistance – Formulation friendly particle size grades and extended technical packages – Delivering DEA-compliant security and production capacity, from kilos to multi-ton supply – Supporting world-class supply security of controlled-substances, from schedule I to schedule III